Premium
Downregulation of caspase‐9 is a frequent event in patients with stage II colorectal cancer and correlates with poor clinical outcome
Author(s) -
Shen X.G.,
Wang C.,
Li Y.,
Wang L.,
Zhou B.,
Xu B.,
Jiang X.,
Zhou Z.G.,
Sun X.F.
Publication year - 2010
Publication title -
colorectal disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.029
H-Index - 89
eISSN - 1463-1318
pISSN - 1462-8910
DOI - 10.1111/j.1463-1318.2009.02009.x
Subject(s) - medicine , colorectal cancer , downregulation and upregulation , stage (stratigraphy) , oncology , outcome (game theory) , event (particle physics) , cancer , gene , paleontology , biochemistry , biology , chemistry , physics , mathematics , mathematical economics , quantum mechanics
Objective To evaluate the clinical significance of caspase‐9 mRNA expression and investigate its prognostic value in stage II colorectal cancer. Method Quantitative real‐time RT–PCR was used to analyse caspase‐9 mRNA expression in cancer tissue and corresponding normal mucosa from 120 patients. Results Compared with normal mucosa, the expression of caspase‐9 mRNA was found to be downregulated in cancer tissue ( P = 0.001). Poorly differentiated cancer showed lower mRNA expression than cancer with greater differentiation ( P = 0.031). The Kaplan–Meier survival analysis demonstrated that patients with downregulated caspase‐9 showed a worse overall survival ( P = 0.012) and disease‐free survival ( P = 0.022). Cox’s proportional hazards regression model confirmed that expression of caspase‐9 was the strongest prognostic factor in stage II colorectal cancer. Conclusion The mRNA expression of caspase‐9 can be used as an independent prognostic factor for patients with stage II colorectal cancer.